तुलना करने के लिए मीट्रिक्स | 328130 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध328130पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −27.6x | −4.2x | −0.5x | |
PEG अनुपात | −18.88 | −0.04 | 0.00 | |
क़ीमत/बुक | 9.5x | 1.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 15.7x | 7.1x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | −32.7% | 39.1% | 48.3% | |
उचित मूल्य अपसाइड | अनलॉक करें | 17.9% | 5.6% | अनलॉक करें |
Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations; with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development; and with Daiichi Sankyo Company, Limited to accelerate biomarker discovery and translational research. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.